Author archives: Zacks Equity Research

Immunovant’s (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

The FDA approves Sanofi’s (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

BankUnited (BKU) announces a new $150-million share repurchase program. The company has also declares regular quarterly dividends, which, along with buybacks, keep enhancing shareholder value.

STMicroelectronics, BP and Asbury Automotive Group are included in this blog.

TEGNA Inc. (TGNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the…

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.

Xilinx (XLNX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Robert Half (RHI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Marathon Oil (MRO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.